THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, July 05, 2021
Patients with primary axillary (underarm) hyperhidrosis are given 15 percent sofpironium bromide gel in both studies.
FREMONT, CA: Brickell Biotech, a clinical-stage pharmaceutical company, aimed at developing innovative and differentiated prescription therapeutics for the diagnosis of debilitating skin diseases, recently announced that the final patient in Phase 3 pivotal Cardigan I study has completed the study and that all planned patients have been enrolled in Phase 3 pivotal Cardigan II study. Patients with primary axillary (underarm) hyperhidrosis are given 15 percent sofpironium bromide gel in both studies.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“This is truly an exciting time for the Brickell team, as we have now completed enrollment in both of our Phase 3 pivotal clinical studies of sofpironium bromide gel, 15 percent. Also, since completing enrollment in the Cardigan I study in April, the last hyperhidrosis patient enrolled has completed the study,” said Deepak Chadha, Chief Research and Development Officer, Brickell. “On behalf of Brickell, I want to take this opportunity to thank the patients and investigators who participated in the Cardigan I study, as well as those currently participating in the Cardigan II study. We remain focused on completing the Cardigan II study as planned and reporting topline results from the Phase 3 program in the fourth quarter of 2021. We look forward to sharing updates on the progress of the Phase 3 pivotal clinical studies over the coming months.”
U.S. Phase 3 Cardigan I and Cardigan II Studies
Cardigan I and Cardigan II are two critical clinical studies in Brickells' Phase 3 clinical program for sofpironium bromide gel in the United States. A total of 350 people aged nine and up with primary axillary hyperhidrosis have participated in each research. The studies are multicenter, randomized, double-blind, vehicle (placebo)-controlled trials assessing the efficacy and safety of topically applied sofpironium bromide gel, 15 percent. The subjects will apply 15 percent sofpironium bromide gel or placebo to their underarms once daily at bedtime for six weeks, with a 2-week follow-up.
The proportion of subjects achieving at least a 2-point improvement on the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) scale, a proprietary and validated patient-reported outcome measure, and change in Gravimetric Sweat Production (GSP), both from baseline to end of treatment, are the co-primary efficacy endpoints in both studies. Throughout the investigations, safety and tolerability assessments will be carried out.
In the fourth quarter of 2021, the company plans to release topline results from the Cardigan I and Cardigan II clinical investigations. The findings are likely to form the basis of a prospective New Drug Application (NDA) in the United States for sofpironium bromide gel, 15 percent for treating primary axillary hyperhidrosis if the studies are successful.
More in News